Home > Search Clinical Trials > Cancer - Gastrointestinal
Clinical Trials: Cancer - Gastrointestinal
IRB No. 03-203-2 (Dr. Daniel Rosenberg, PI): Identification and Analysis of Aberrant Crypt Foci in Colonoscopy Patients
Study description not available
IRB No. 19-121JS-1: Ellagic Acid, Urolithins and Colonic Microbial Communities Affected by Walnut Consumption
The purpose of this study is to investigate whether adding walnuts to your diet can have a beneficial effect on your colon. Walnuts contain a natural compound called ellagitannin that is broken down in the stomach to ellagic acid. Ellagic acid is further broken down by your gut microbiota into a group of polyphenolic compounds called urolithins that have powerful anti-inflammatory actions. The gut microbiota is defined as the community of bacteria, fungi, viruses, etc. that live in your gut. Increasing evidence suggests that polyphenol consumption is associated with lower risk of colorectal cancer. We aim to investigate how a person's gut microbiome may contribute to your ability to form these powerful antioxidant urolithin compounds. Antioxidants are a group of substances that have the ability to reduce inflammation. In this study, we will collect demographic information and dietary records, and perform tests on proteins, DNA and/or RNA from samples of colon biopsies, blood, stool and urine to investigate how a person's microbiome may contribute to their ability to form urolithins.
IRB No. 21-001-1 (Dr. Daniel Rosenberg, PI): Determining the Role of Peanut Consumption on Dietary Habits, Gut Microbiome, and Colon Biomarkers in a Healthy Population
Colorectal cancer (CRC) is the second cancer-related cause of death among men and women in the United States. Dietary lifestyle is a contributing factor to CRC risk, and it plays a role in changing the bacteria living in the gut. Current research are now focusing on studying the effects of these bacteria and the compounds they produce, and how it is affecting cancer progression. Peanuts are part of the American diet, a food that is rich in nutrients such as protein, fiber, healthy fats, bioactive compounds, vitamins and minerals. The objective of this study is to determine if increasing peanut intake influences other dietary habits and gut bacteria composition. Secondary aims are as follows: 1) to understand if changes in dietary habits and gut bacteria affect biomarkers in the colon, and 2) to study possible mechanisms in early CRC prevention. Therefore, a dietary intervention will test the effects of peanut intake on dietary habits, gut microbiota, and colon biomarkers. Healthy participants (50-65 years old) scheduled for a screening colonoscopy will be recruited and start a 1-week washout period where they will be asked to avoid peanuts/nuts and other foods provided in a list throughout the study period. Then, they will be randomized into peanut or control group, where control gorup is gender and body mass index matched to peanut group. For 3 weeks, the peanut group will be consuming 2 ounces of roasted peanuts daily, while the control group will not consume peanuts. At baseline and end of clinical trial, blood, stool and 3-day dietary records will be collected. After the intervention, participants will have the colonoscopy done and eight colon biopsy samples will be collected. The hypothesis is that peanut consumption will increase intake of other healthy foods (increase in dietary fiber) and change the bacteria in the gut to a more diverse and rich community when compared to baseline and matched controls. We also expect an increase anti-inflammatory colon biomarker since peanuts contain fiber, unsaturated fats, and antioxidants that may help prevent cancer.